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 Mutations in one of two genes SLC3A1 and SLC7A9 are responsible for the 
majority of cystinuria phenotypes. A defective renal tubular protein transporter 
causes high urinary levels of cystine and the dibasic amino acids, lysine, 
arginine and ornithine. Cystine is relatively insoluble in urine and forms 
stones. We have found 57 different mutations in our UK cohort[1]. Most are 
missense mutations and it is unclear what effect they have on protein function 
and how this translates to phenotype.  
 
The aim of this study was to use protein modelling to investigate how 
missense mutations may affect protein function. Limited experimental data is 
available as experimental techniques are time-consuming and results would 
lag significantly behind the rate at which new mutations are being reported. 
Understanding how individual mutations can cause protein dysfunction could 
allow us to predict a patient’s disease severity and tailor individual 
management more effectively. We modelled the b(0+)AT protein encoded by 
SLC7A9 using the Phyre2 web server, and other validated software [2-5].  
 
The missense mutations were scored by an investigator blind to the clinical 
data into those predicted to cause a low/low-medium effect=1 or high/high-
medium effect=2. This was based on several factors including the proximity of 
the mutation to the predicted functional sites and size of conformational 
change. Large genomic rearrangements were assumed to cause significant 
protein dysfunction therefore all other (non-missense) mutations were 
assigned a score of 2. An overall severity score was calculated for 26 patients 
based on the sum of the score of each individual mutation. For example, a 
patient with a predicted low-effect missense mutation and a frameshift 
mutation would score 3 (1+2).  
 
When comparing patients with a score of 4 versus a score of 3, there was no 
difference between the levels of cystine(201 µmol/mmolCr  IQR 161 to 231 vs 
154 µmol/mmolCr  IQR 133.7 to 191.3, p=0.2545) or lysine (629.5 
µmol/mmolCr  IQR 593.2 to 814.6 vs 569.5 µmol/mmolCr  IQR 403.6 to 807.5, 
p=0.2887). Patients who scored 4 had higher levels of arginine(383 
µmol/mmolCr  IQR 283 to 392.7 vs 70 µmol/mmolCr  IQR 36.38 to 237.3, 
p=0.0151) and ornithine(120.2 µmol/mmolCr IQR 97.67 to 153.1 vs 94 
µmol/mmolCr  IQR 68.38 to 111, p=0.0482) than patients who scored 3. They 
also experienced a higher number of stone episodes(0.5/yr IQR 0.0 to 1.0 vs 
0.0/yr IQR 0 to 0.3, p=0.0451). Only three patients scored less than 3, 
precluding statistical analysis.  
 
Our results suggest our model may help determine a patient’s phenotype. The 
lack of statistical difference for cystine and lysine may be explained by 
limitations in cystine measurements and other transporter mechanisms 
involved in lysine transport.  
 
Clearly, a patient’s genotype can only determine part of a patient’s disease 
profile, which may also be influenced by modifier genes and complex genetic 
and environmental interactions. More collaborative work is needed to explore 
our hypothesis. This approach has given us insight into how the different 
missense mutations may cause the range of phenotypes seen in Cystinuria 
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Figure 1 Structural analysis of mutations present in b(0+)AT. A) A structural model of  
b(0+)AT was generated and residues involved in amino acid transport identified (cyan) and 
mutations mapped on (red) to analyse their potential structural and functional effect. B) 
p.Gly105Arg is located at the end of the channel where amino acids are transported. C) 
Some mutations (p.Arg171Trp, p.Arg333Trp) are located close to the end of the membrane 
and could affect stability in the membrane. 
 
 
